Future Therapeutics in Alzheimer’s Disease: Development Status of BACE Inhibitors

BioDrugs

Volumn 30, Issue 3, 2016, Pages 173-194

  Evin, Genevieve ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADUCANUMAB; ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; AVAGACESTAT; AZD 3293; BAPINEUZUMAB; BEGACESTAT; BETA SECRETASE INHIBITOR; CHF 5074; CREMAZUMAB; CTS 21166; E2609; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; JNJ 54861911; LY 2811376; LY 2886721; NONSTEROID ANTIINFLAMMATORY AGENT; OLIGOMER; PEPTIDOMIMETIC AGENT; SECRETASE; SOLANEZUMAB; TARENFLURBIL; UNCLASSIFIED DRUG; VANUTIDE CRIDIFICAR; VERUBECESTAT; 4-METHOXY-5'-METHYL-6'-(5-(PROP-1-YN-1-YL)PYRIDIN-3-YL)-3'H-DISPIRO(CYCLOHEXANE-1,2'-INDEN-1',2'-IMIDAZOL)-4'-AMINE; ENZYME INHIBITOR; IMIDAZOLE DERIVATIVE; MOLECULAR LIBRARY; SPIRO COMPOUND; SULFOXIDE; THIADIAZINE DERIVATIVE;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; COGNITION; DRUG INDUSTRY; ENZYME INHIBITION; FIBER; FUTUROLOGY; HUMAN; NONHUMAN; PASSIVE IMMUNIZATION; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; ANTAGONISTS AND INHIBITORS; IMMUNOTHERAPY; METABOLISM; MOLECULAR LIBRARY; MOLECULARLY TARGETED THERAPY; PHARMACOLOGY; PROCEDURES; VACCINATION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID PRECURSOR PROTEIN SECRETASES; CYCLIC S-OXIDES; ENZYME INHIBITORS; HUMANS; IMIDAZOLES; IMMUNIZATION, PASSIVE; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; PEPTIDOMIMETICS; SMALL MOLECULE LIBRARIES; SPIRO COMPOUNDS; THIADIAZINES; VACCINATION;

EID: 84962295042     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.1007/s40259-016-0168-3     Document Type: Review

References (192)

1. Reitz C, Mayeux R. Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem Pharmacol. 2014;88:640–51.
2. Perl DP. Neuropathology of Alzheimer’s Disease. Mt Sinai J Med. 2010;77:32–42.
3. Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med. 2011;1:a006189.
4. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA. 1985;82:4245–9.
5. Sheng M, Sabatini BL, Südhof TC. Synapses and Alzheimer’s disease. Cold Spring Harb Perspect Biol. 2012;4:pii: a005777.
6. Benilova I, Karran E, De Strooper B. The toxic Abeta oligomer and Alzheimer’s disease: an emperor in need of clothes. Nat Neurosci. 2012;15:349–57.
7. Iqbal K, Liu F, Gong C-X. Tau and neurodegenerative disease: the story so far. Nat Rev Neurol. 2016;12:15–27.
8. Mondragón-Rodríguez S, Perry G, Zhu X, Boehm J. Amyloid beta and tau proteins as therapeutic targets for Alzheimer’s disease treatment: rethinking the current strategy. Int J Alzheimers Dis. 2012;2012:630182.
9. Mudher A, Lovestone S. Alzheimer’s disease—do tauists and baptists finally shake hands? Trends Neurosci. 2002;25:22–6.
10. Lonskaya I, Hebron M, Chen W, Schachter J, Moussa C. Tau deletion impairs intracellular β-amyloid-42 clearance and leads to more extracellular plaque deposition in gene transfer models. Mol Neurodegen. 2014;9:46.
11. Dubey J, Ratnakaran N, Koushika SP. Neurodegeneration and microtubule dynamics: death by a thousand cuts. Front Cell Neurosci. 2015;9:343.
12. Kovacs GG. Invited review: Neuropathology of tauopathies: principles and practice. Neuropathol Appl Neurobiol. 2015;41:3–23.
13. Kang J, Lemaire H-G, Unterbeck A, Salbaum JM, Masters CL, Grzeschik K-H, et al. The precursor of Alzheimer’s disease amyloid A4 protein resembles a cell-surface receptor. Nature. 1987;325:733–6.
14. Nhan HS, Chiang K, Koo EH. The multifaceted nature of amyloid precursor protein and its proteolytic fragments: friends and foes. Acta Neuropathol. 2015;129:1–19.
15. Nalivaeva NN, Turner AJ. The amyloid precursor protein: a biochemical enigma in brain development, function and disease. FEBS Lett. 2013;587:2046–54.
16. O’Brien RJ, Wong PC. Amyloid precursor protein processing and Alzheimer’s disease. Annu Rev Neurosci. 2011;34:185–204.
17. Haass C, Kaether C, Thinakaran G, Sisodia S. Trafficking and proteolytic processing of APP. Cold Spring Harb Perspect Med. 2012;2012:2.
18. Pardossi-Piquard R, Checler F. The physiology of the beta-amyloid precursor protein intracellular domain AICD. J Neurochem. 2012;120(Suppl 1):109–24.
19. Cao X, Sudhof TC. A transcriptionally [correction of transcriptively] active complex of APP with Fe65 and histone acetyltransferase Tip60. Science. 2001;293:115–20.
20. Iwatsubo T. The gamma-secretase complex: machinery for intramembrane proteolysis. Curr Opin Neurobiol. 2004;14:379–83.
21. Tomita T. Molecular mechanism of intramembrane proteolysis by γ-secretase. J. Biochem. 2014;156:195–201.
22. Lammich S, Kojro E, Postina R, Gilbert S, Pfeiffer R, Jasionowski M, et al. Constitutive and regulated alpha-secretase cleavage of Alzheimer’s amyloid precursor protein by a disintegrin metalloprotease. Proc Natl Acad Sci USA. 1999;96:3922–7.
23. Buxbaum JD, Liu KN, Luo Y, Slack JL, Stocking KL, Peschon JJ, et al. Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor. J Biol Chem. 1998;273:27765–7.
24. Chami L, Checler F. BACE1 is at the crossroad of a toxic vicious cycle involving cellular stress and beta-amyloid production in Alzheimer’s disease. Mol Neurodegen. 2012;7:52.
25. Tamagno E, Guglielmotto M, Monteleone D, Vercelli A, Tabaton M. Transcriptional and post-transcriptional regulation of β-secretase. IUBMB Life. 2012;64:943–50.
26. Tan J, Li QX, Ciccotosto G, Crouch PJ, Culvenor JG, White AR, et al. Mild oxidative stress induces redistribution of BACE1 in non-apoptotic conditions and promotes the amyloidogenic processing of Alzheimer’s disease amyloid precursor protein. PloS One. 2013;8:e61246.
27. Baranello RJ, Bharani KL, Padmaraju V, Chopra N, Lahiri DK, Greig NH, et al. Amyloid-beta protein clearance and degradation (ABCD) pathways and their role in Alzheimer’s disease. Curr Alzheimer Res. 2015;12:32–46.
28. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer’s amyloid β-peptide. Nat Rev Mol Cell Biol. 2007;8:101–12.
29. Haass C, Hung AY, Schlossmacher MG, Oltersdorf T, Teplow DB, Selkoe DJ. Normal cellular processing of the β-amyloid precursor protein results in the secretion of the amyloid β peptide and related molecules. Ann N Y Acad Sci. 1993;695(1):109–16.
30. Hardy JA, Higgins GA. Alzheimer’s disease: the amyloid cascade hypothesis. Science. 1992;256:184–5.
31. Schellenberg G, Montine T. The genetics and neuropathology of Alzheimer’s disease. Acta Neuropathol. 2012;124:305–23.
32. Tanzi RE, Kovacs DM, Kim T-W, Moir RD, Guenette SY, Wasco W. REVIEWThe Gene Defects Responsible for Familial Alzheimer’s Disease. Neurobiol Dis. 1996;3:159–68.
33. Citron M, Oltersdorf T, Haass C, McConlogue L, Hung AY, Seubert P, et al. Mutation of the [beta]-amyloid precursor protein in familial Alzheimer’s disease increases β-protein production. Nature. 1992;360:672–4.
34. Herl L, Thomas AV, Lill CM, Banks M, Deng A, Jones PB, et al. Mutations in amyloid precursor protein affect its interactions with presenilin/γ-secretase. Mol Cell Neurosci. 2009;41:166–74.
35. Ancolio K, Dumanchin C, Barelli H, Warter JM, Brice A, Campion D, et al. Unusual phenotypic alteration of β amyloid precursor protein (βAPP) maturation by a new Val-715 – > Met betaAPP-770 mutation responsible for probable early-onset Alzheimer’s disease. Proc Natl Acad Sci USA. 1999;96:4119–24.
36. Czech C, Tremp G, Pradier L. Presenilins and Alzheimer’s disease: biological functions and pathogenic mechanisms. Progr Neurobiol. 2000;60:363–84.
37. Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S, et al. A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline. Nature. 2012;488:96–9.
38. Lambert J-C, Amouyel P. Genetics of Alzheimer’s disease: new evidences for an old hypothesis? Curr Opin Genet Dev. 2011;21:295–301.
39. Kim M, Suh J, Romano D, Truong MH, Mullin K, Hooli B, et al. Potential late-onset Alzheimer’s disease-associated mutations in the ADAM10 gene attenuate alpha-secretase activity. Hum Mol Genet. 2009;18:3987–96.
40. Lambert J-C, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nat enet. 2013;45:1452–8.
41. Calero M, Gómez-Ramos A, Calero O, Soriano E, Avila J, Medina M. Additional mechanisms conferring genetic susceptibility to Alzheimer’s disease. Front Cell Neurosci. 2015;9:138.
42. Karch CM, Goate AM. Alzheimer’s disease risk genes and mechanisms of disease pathogenesis. Biol Psychiatry. 2015;77:43–51.
43. Fagan T. Alzheimer’s GWAS Hits Point to Endosomes, Synapses. Published 13/11/2015. http://www.alzforum.org/news/conference-coverage/alzheimers-gwas-hits-point-endosomes-synapses.
44. Ingram DK. Vaccine development for Alzheimer’s disease: a shot of good news. Trends Neurosci. 2001;24:305–7.
45. Solomon B. Immunological approaches as therapy for Alzheimer’s disease. Expert Opin Biol Ther. 2002;2:907–17.
46. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400:173–7.
47. Serrano-Pozo A, William CM, Ferrer I, Uro-Coste E, Delisle M-B, Maurage C-A, et al. Beneficial effect of human anti-amyloid-β active immunization on neurite morphology and tau pathology. Brain. 2010;133:1312–27.
48. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, et al. Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005;64:1553–62.
49. Wisniewski T, Goñi F. Immunotherapeutic Approaches for Alzheimer’s Disease. Neuron. 2015;85:1162–76.
50. Winblad B, Andreasen N, Minthon L, Floesser A, Imbert G, Dumortier T, et al. Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer’s disease: randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol. 2015;11:597–604.
51. Farlow MR, Andreasen N, Riviere M-E, Vostiar I, Vitaliti A, Sovago J, et al. Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer’s disease. Alzheimers Res Ther. 2015;7(1):23.
52. Alzforum website. Therapeutics, CAD106. http://www.alzforum.org/therapeutics/cad106. Accessed 03 March 2016.
53. Arai H, Suzuki H, Yoshiyama T. Vanutide Cridificar and the QS-21 adjuvant in Japanese subjects with mild to moderate Alzheimer’s disease: results from two phase 2 studies. Curr Alzheimer Res. 2015;12:242–54.
54. Mandler M, Santic R, Gruber P, Cinar Y, Pichler D, Funke SA, et al. Tailoring the antibody response to aggregated aβ using novel alzheimer-vaccines. PLoS One. 2015;10:e0115237.
55. Bock J. Breakthrough in Alzheimer’s Disease: AFFiRiS halted clinical progression in Alzheimer patients upon treatment with AD04 in a phase II clinical study. AFFiRiS website; 2014. http://www.affiris.com/pdf/presse_medien/pressemeldungen/14_Final_PK_PhaseII_E_0603.pdf. Accessed 03 March 2016.
56. Bard F, Cannon C, Barbour R, Burke R-L, Games D, Grajeda H, et al. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000;6:916–9.
57. DeMattos RB, Bales KR, Cummins DJ, Dodart J-C, Paul SM, Holtzman DM. Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci USA. 2001;98:8850–5.
58. Dodart J-C, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, et al. Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer’s disease model. Nat Neurosci. 2002;5:452–7.
59. Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology. 2009;73:2061–70.
60. 11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer’s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010;9:363–72.
61. Blennow K, Zetterberg H, Rinne JO, et al. EFfect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate alzheimer disease. Arch Neurol. 2012;69:1002–10.
62. Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med. 2014;370:322–33.
63. Liu E, Schmidt ME, Margolin R, Sperling R, Koeppe R, Mason NS, Klunk WE, Mathis CA, Salloway S, Fox NC, Hill DL, Les AS, Collins P, Gregg KM, Di J, Lu Y, Tudor IC, Wyman BT, Booth K, Broome S, Yuen E, Grundman M, Brashear HR, Bapineuzumab 301 and 302 Clinical Trial Investigators. Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials. Neurology. 2015;85:692–700.
64. Busche MA, Grienberger C, Keskin AD, Song B, Neumann U, Staufenbiel M, et al. Decreased amyloid-β and increased neuronal hyperactivity by immunotherapy in Alzheimer’s models. Nat Neurosci. 2015;18:1725–7.
65. Farlow M, Arnold SE, van Dyck CH, Aisen PS, Snider BJ, Porsteinsson AP, et al. Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease. Alzheimers Dement. 2012;8:261–71.
66. Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. Phase 3 Trials of solanezumab for mild-to-moderate Alzheimer’s disease. N Engl J Med. 2014;370:311–21.
67. Siemers ER, Sundell KL, Carlson C, Case M, Sethuraman G, Liu-Seifert H, et al. Phase 3 solanezumab trials: secondary outcomes in mild Alzheimer’s disease patients. Alzheimers Dement. 2015;pii: S1552-5260:02148-2.
68. Gandy S, Sano M. Alzheimer disease: Solanezumab: prospects for meaningful interventions in AD? Nat Rev Neurol. 2015;11:669–70.
69. Adolfsson O, Pihlgren M, Toni N, Varisco Y, Buccarello AL, Antoniello K, et al. An effector-reduced anti-β-amyloid (Aβ) antibody with unique Aβ binding properties promotes neuroprotection and glial engulfment of Aβ. J Neurosci. 2012;32:9677–89.
70. Ostrowitzki S, Deptula D, Thurfjell L, et al. Mechanism of amyloid removal in patients with alzheimer disease treated with gantenerumab. Arch Neurol. 2012;69:198–207.
71. Roche. Roche provides update on gantenerumab development programme. Roche website; 19/12/2014. http://www.roche.com/media/store/releases/med-cor-2014-12-19b.htm. Accessed 03 March 2016.
72. Strobel G. Biogen antibody buoyed by phase 1 data and hungry investors. Alzforum website 25/03/2015. http://www.alzforum.org/news/conference-coverage/biogen-antibody-buoyed-phase-1-data-and-hungry-investors. Accessed 03 March 2016.
73. Evin G, Cappai R, Li QX, Culvenor JG, Small DH, Beyreuther K, et al. Candidate gamma-secretases in the generation of the carboxyl terminus of the Alzheimer’s disease beta A4 amyloid: possible involvement of cathepsin D. Biochemistry. 1995;34:14185–92.
74. Higaki J, Catalano R, Guzzetta AW, Quon D, Navé J-F, Tarnus C, et al. Processing of β-amyloid precursor protein by cathepsin D. J Biol Chem. 1996;271:31885–93.
75. Shearman MS, Beher D, Clarke EE, Lewis HD, Harrison T, Hunt P, et al. L-685,458, an aspartyl protease transition state mimic, is a potent inhibitor of amyloid beta-protein precursor gamma-secretase activity. Biochemistry. 2000;39:8698–704.
76. Wolfe MS, Citron M, Diehl TS, Xia W, Donkor IO, Selkoe DJ. A substrate-based difluoro ketone selectively inhibits Alzheimer’s gamma-secretase activity. J Med Chem. 1998;41:6–9.
77. Esler WP, Kimberly WT, Ostaszewski BL, Ye W, Diehl TS, Selkoe DJ, et al. Activity-dependent isolation of the presenilin- gamma -secretase complex reveals nicastrin and a gamma substrate. Proc Natl Acad Sci USA. 2002;5(99):2720–5.
78. Tian G, Sobotka-Briner CD, Zysk J, Liu X, Birr C, Sylvester MA, et al. Linear non-competitive inhibition of solubilized human gamma-secretase by pepstatin A methylester, L685458, sulfonamides, and benzodiazepines. J Biol Chem. 2002;277:31499–505.
79. Li YM, Xu M, Lai MT, Huang Q, Castro JL, DiMuzio-Mower J, et al. Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1. Nature. 2000;405:689–94.
80. Wolfe MS, Xia W, Ostaszewski BL, Diehl TS, Kimberly WT, Selkoe DJ. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature. 1999;398:513–7.
81. Evin G, Sharples RA, Weidemann A, Reinhard FB, Carbone V, Culvenor JG, et al. Aspartyl protease inhibitor pepstatin binds to the presenilins of Alzheimer’s disease. Biochemistry. 2001;40:8359–68.
82. Seiffert D, Bradley JD, Rominger CM, Rominger DH, Yang F, Meredith JE, et al. Presenilin-1 and -2 are molecular targets for γ-secretase inhibitors. J Biol Chem. 2000;275:34086–91.
83. Dovey HF, John V, Anderson JP, Chen LZ, de Saint Andrieu P, Fang LY, et al. Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J Neurochem. 2001;76:173–81.
84. De Strooper B, Annaert W, Cupers P, Saftig P, Craessaerts K, Mumm JS, et al. A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature. 1999;398:518–22.
85. Kopan R. Notch signaling. Cold Spring Harb Perspect Biol. 2012;4:a011213.
86. Wong GT, Manfra D, Poulet FM, Zhang Q, Josien H, Bara T, et al. Chronic treatment with the γ-secretase inhibitor LY-411,575 inhibits β-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem. 2004;279:12876–82.
87. Henley DB, May PC, Dean RA, Siemers ER. Development of semagacestat (LY450139), a functional γ-secretase inhibitor, for the treatment of Alzheimer’s disease. Expert Opin Pharmacother. 2009;10:1657–64.
88. Bateman RJ, Siemers ER, Mawuenyega KG, Wen G, Browning KR, Sigurdson WC, et al. A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Ann Neurol. 2009;66:48–54.
89. Fleisher AS, Raman R, Siemers ER, Becerra L, Clark CM, Dean RA, et al. Phase II safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer’s disease. Arch Neurol. 2008;65:1031–8.
90. Gillman KW, Starrett JE, Parker MF, Xie K, Bronson JJ, Marcin LR, et al. Discovery and evaluation of BMS-708163, a potent, selective and orally bioavailable γ-secretase inhibitor. ACS Med Chem Lett. 2010;1:120–4.
91. Albright CF, Dockens RC, Meredith JE, Olson RE, Slemmon R, Lentz KA, et al. Pharmacodynamics of selective inhibition of γ-secretase by avagacestat. J Pharmacol Exp Ther. 2013;344:686–95.
92. Tong G, Wang J-S, Sverdlov O, Huang S-P, Slemmon R, Croop R, et al. Multicenter, randomized, double-blind, placebo-controlled, single-ascending dose study of the oral γ-secretase inhibitor BMS-708163 (avagacestat): tolerability profile, pharmacokinetic parameters, and pharmacodynamic markers. Clin Ther. 2012;34:654–67.
93. Tong G, Wang J-S, Sverdlov O, Huang S-P, Slemmon R, Croop R, et al. A contrast in safety, pharmacokinetics and pharmacodynamics across age groups after a single 50 mg oral dose of the γ-secretase inhibitor avagacestat. Br J Clin Pharmacol. 2013;75(1):136–45.
94. Coric V, van Dyck CH, Salloway S, et al. Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate alzheimer disease. Arch Neurol. 2012;69:1430–40.
95. Coric V, Salloway S, van Dyck CH, et al. Targeting prodromal alzheimer disease with avagacestat: a randomized clinical trial. JAMA Neurol. 2015;72:1324–33.
96. Martone RL, Zhou H, Atchison K, Comery T, Xu JZ, Huang X, et al. Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein γ-secretase for the treatment of Alzheimer’s disease. J Pharmacol Exp Ther. 2009;331:598–608.
97. Niva C, Parkinson J, Olsson F, van Schaick E, Lundkvist J, Visser SG. Has inhibition of Aβ production adequately been tested as therapeutic approach in mild AD? A model-based meta-analysis of γ-secretase inhibitor data. Eur J Clin Pharmacol. 2013;69:1247–60.
98. Szaruga M, Veugelen S, Benurwar M, Lismont S, Sepulveda-Falla D, Lleo A, et al. Qualitative changes in human γ-secretase underlie familial Alzheimer’s disease. J Exp Med. 2015;212:2003–13.
99. Chávez-Gutiérrez L, Bammens L, Benilova I, Vandersteen A, Benurwar M, Borgers M, et al. The mechanism of γ-Secretase dysfunction in familial Alzheimer disease. EMBO J. 2012;31:2261–74.
100. Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, et al. A subset of NSAIDs lower amyloidogenic A[beta]42 independently of cyclooxygenase activity. Nature. 2001;414:212–6.
101. Green RC, Schneider LS, Amato DA, et al. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild alzheimer disease: a randomized controlled trial. JAMA. 2009;302:2557–64.
102. Takagi-Niidome S, Sasaki T, Osawa S, Sato T, Morishima K, Cai T, et al. Cooperative roles of hydrophilic loop 1 and the C-terminus of presenilin 1 in the substrate-gating mechanism of γ-secretase. J Neurosci. 2015;35:2646–56.
103. X-c Bai, Yan C, Yang G, Lu P, Ma D, Sun L, et al. An atomic structure of human γ-secretase. Nature. 2015;525:212–7.
104. Chen F, Hasegawa H, Schmitt-Ulms G, Kawarai T, Bohm C, Katayama T, et al. TMP21 is a presenilin complex component that modulates γ-secretase but not ε-secretase activity. Nature. 2006;440:1208–12.
105. Wang J, Lu R, Yang J, Li H, He Z, Jing N, et al. TRPC6 specifically interacts with APP to inhibit its cleavage by γ-secretase and reduce Aβ production. Nat Commun. 2015;6:8876.
106. He G, Luo W, Li P, Remmers C, Netzer WJ, Hendrick J, et al. Gamma-secretase activating protein is a therapeutic target for Alzheimer’s disease. Nature. 2010;467:95–8.
107. Hussain I, Fabrègue J, Anderes L, Ousson S, Borlat F, Eligert V, et al. The role of γ-secretase activating protein (GSAP) and imatinib in the regulation of γ-secretase activity and amyloid-β generation. J Biol Chem. 2013;288:2521–31.
108. De Strooper B. Chávez Gutiérrez L. Learning by failing: ideas and concepts to tackle γ-secretases in Alzheimer’s disease and beyond. Annu Rev Pharmacol Toxicol. 2015;55:419–37.
109. Vassar R. The β-secretase, BACE. J Mol Neurosci. 2001;17:157–70.
110. Roberds SL, Anderson J, Basi G, Bienkowski MJ, Branstetter DG, Chen KS, et al. BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer’s disease therapeutics. Hum Mol Genet. 2001;10:1317–24.
111. Luo Y, Bolon B, Kahn S, Bennett BD, Babu-Khan S, Denis P, et al. Mice deficient in BACE1, the Alzheimer’s beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat Neurosci. 2001;4:231–2.
112. Zhao J, Fu Y, Yasvoina M, Shao P, Hitt B, O’Connor T, et al. β-site amyloid precursor protein cleaving enzyme 1 levels become elevated in neurons around amyloid plaques: implications for Alzheimer’s disease pathogenesis. J Neurosci. 2007;27:3639–49.
113. Holsinger RM, McLean CA, Beyreuther K, Masters CL, Evin G. Increased expression of the amyloid precursor beta-secretase in Alzheimer’s disease. Ann Neurol. 2002;51:783–6.
114. Fukumoto H, Cheung BS, Hyman BT, Irizarry MC. Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease. Arch Neurol. 2002;59:1381–9.
115. Li R, Lindholm K, Yang LB, Yue X, Citron M, Yan R, et al. Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer’s disease patients. Proc Natl Acad Sci USA. 2004;101:3632–7.
116. Hong L, Koelsch G, Lin X, Wu S, Terzyan S, Ghosh A, et al. Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor. Science. 2000;290:150–3.
117. Farzan M, Schnitzler CE, Vasilieva N, Leung D, Choe H. BACE2, a beta -secretase homolog, cleaves at the beta site and within the amyloid-beta region of the amyloid-beta precursor protein. Proc Natl Acad Sci USA. 2000;97:9712–7.
118. Acquati F, Accarino M, Nucci C, Fumagalli P, Jovine L, Ottolenghi S, et al. The gene encoding DRAP (BACE2), a glycosylated transmembrane protein of the aspartic protease family, maps to the Down critical region. FEBS Lett. 2000;468:59–64.
119. Saunders AJ, Kim T-W, Tanzi RE. BACE Maps to Chromosome 11 and a BACE homolog, BACE2, reside in the obligate Down syndrome region of chromosome 21. Science. 1999;286:1255.
120. Hussain I, Powell DJ, Howlett DR, Chapman GA, Gilmour L, Murdock PR, et al. ASP1 (BACE2) cleaves the amyloid precursor protein at the β-secretase site. Mol Cell Neurosci. 2000;16:609–19.
121. Fluhrer R, Capell A, Westmeyer G, Willem M, Hartung B, Condron MM, et al. A non-amyloidogenic function of BACE-2 in the secretory pathway. J Neurochem. 2002;81:1011–20.
122. Yan R, Han P, Miao H, Greengard P, Xu H. The transmembrane domain of the Alzheimer’s β-secretase (BACE1) determines its late Golgi localization and access to β-amyloid precursor protein (APP) substrate. J Biol Chem. 2001;276:36788–96.
123. Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, et al. Beta-secretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 1999;286:735–41.
124. Bennett BD, Babu-Khan S, Loeloff R, Louis JC, Curran E, Citron M, et al. Expression analysis of BACE2 in brain and peripheral tissues. J Biol Chem. 2000;275:20647–51.
125. Esterházy D, Stützer I, Wang H, Rechsteiner Markus P, Beauchamp J, Döbeli H, et al. Bace2 is a β cell-enriched protease that regulates pancreatic β cell function and mass. Cell Metabol. 2011;14:365–77.
126. Rochin L, Hurbain I, Serneels L, Fort C, Watt B, Leblanc P, et al. BACE2 processes PMEL to form the melanosome amyloid matrix in pigment cells. Proc Natl Acad Sci USA. 2013;110:10658–63.
127. Stützer I, Selevsek N, Esterházy D, Schmidt A, Aebersold R, Stoffel M. Systematic proteomic analysis identifies β-site amyloid precursor protein cleaving enzyme 2 and 1 (BACE2 and BACE1) substrates in pancreatic β-cells. J Biol Chem. 2013;288:10536–47.
128. Evin G, Lessene G, Wilkins S. BACE inhibitors as potential drugs for the treatment of Alzheimer’s disease: focus on bioactivity. Recent Pat CNS Drug Discov. 2011;6:91–106.
129. Evin G, Kenche VB. BACE inhibitors as potential therapeutics for Alzheimer’s disease. Recent Pat CNS Drug Discov. 2007;2:188–99.
130. Ghosh AK, Brindisi M, Tang J. Developing β-secretase inhibitors for treatment of Alzheimer’s disease. J Neurochem. 2012;120:71–83.
131. Park H, Lee S. Determination of the active site protonation state of β-secretase from molecular dynamics simulation and docking experiment: implications for structure-based inhibitor design. J Am Chem Soc. 2003;125:16416–22.
132. McGaughey GB, Holloway MK. Structure-guided design of β-secretase (BACE-1) inhibitors. Expert Opin Drug Discov. 2007;2:1129–38.
133. Hussain I, Hawkins J, Harrison D, Hille C, Wayne G, Cutler L, et al. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases β-cleavage of amyloid precursor protein and amyloid-beta production in vivo. J Neurochem. 2007;100:802–9.
134. Ghosh AK, Kumaragurubaran N, Hong L, Kulkarni SS, Xu X, Chang W, et al. Design, synthesis, and X-ray structure of potent memapsin 2 (β-secretase) inhibitors with isophthalamide derivatives as the P2-P3-ligands. J Med Chem. 2007;17(50):2399–407.
135. Yu J, Koelsch G, Li A, Turner RT, Bilcer GM, Grove C, et al. In vivo efficacy of BACE-1 inhibitor CTS21166 (ASP1702) in rat CNS compartments. Alzheimers Dement. 2009;5:P430–1.
136. Chang WP, Huang X, Downs D, Cirrito JR, Koelsch G, Holtzman DM, et al. Beta-secretase inhibitor GRL-8234 rescues age-related cognitive decline in APP transgenic mice. FASEB J. 2011;25:775–84.
137. Oehlrich D, Prokopcova H, Gijsen HJM. The evolution of amidine-based brain penetrant BACE1 inhibitors. Bioorg Med Chem Lett. 2014;24:2033–45.
138. May PC, Dean RA, Lowe SL, Martenyi F, Sheehan SM, Boggs LN, et al. Robust central reduction of amyloid-beta in humans with an orally available, non-peptidic β-secretase inhibitor. J Neurosci. 2011;31:16507–16.
139. May P, Boggs L, Brier R, Calligaro D, Citron M, Day T, et al. Preclinical characterization of LY2886721: A BACE1 inhibitor in clinical development for early Alzheimer’s disease. Alzheimers Dement. 2012;8:P95.
140. May PC, Willis BA, Lowe SL, Dean RA, Monk SA, Cocke PJ, et al. The potent BACE1 inhibitor LY2886721 elicits robust central aβ pharmacodynamic responses in mice, dogs, and humans. J Neurosci. 2015;35:1199–210.
141. Jeppsson F, Eketjall S, Janson J, Karlstrom S, Gustavsson S, Olsson L-L, et al. Discovery of AZD3839, a potent and selective BACE1 inhibitor clinical candidate for the treatment of Alzheimer disease. J Biol Chem. 2012;287:41245–57.
142. Quartino A, Huledal G, Sparve E, Lüttgen M, Bueters T, Karlsson P, et al. Population pharmacokinetic and pharmacodynamic analysis of plasma Aβ40 and Aβ42 following single oral doses of the BACE1 inhibitor AZD3839 to healthy volunteers. Clin Pharmacol Drug Dev. 2014;3:396–405.
143. Sparve E, Quartino AL, Lüttgen M, Tunblad K, Gårdlund AT, Fälting J, et al. Prediction and modeling of effects on the QTc interval for clinical safety margin assessment, based on single-ascending-dose study data with AZD3839. J Pharmacol Exp Therapeut. 2014;350:469–78.
144. Vitae. Positive top-line results achieved from two phase 1 clinical trials of BACE inhibitor BI1181181/VTP-37948 in Alzheimer’s disease. Viate Pharmaceuticals website. http://ir.vitaepharma.com/phoenix.zhtml?c=219654&p=irol-newsArticle&ID=1981037. 23 Oct 2013.
145. Rueeger H, Lueoend R, Machauer R, Veenstra SJ, Jacobson LH, Staufenbiel M, et al. Discovery of cyclic sulfoxide hydroxyethylamines as potent and selective β-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure based design and in vivo reduction of amyloid β-peptides. Bioorg Med Chem Lett. 2013;23:5300–6.
146. Neumann U, Rueeger H, Machauer R, Veenstra S, Lueoend R, Tintelnot-Blomley M, et al. A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in APP transgenic mice. Mol Neurodegener. 2015;10:44.
147. Hyde L, Chen X, Stahl L, Sondey M, Scott J, Cumming J, et al. Chronic BACE inhibition dramatically slows the rate of Aβ accumulation and the development of amyloid plaques in young TgCRND8 mice. Alzheimers Dement. 2012;8:P188.
148. Kennedy M, Scott J, Cantu C, Chen X, Kuvelkar R, Werner B, et al. Preclinical profile of MK-8931, a structurally novel, centrally-active, β-secretase (BACE1) inhibitor for the treatment of Alzheimer’s disease. 12th International Conference AD/PD, Nice, France, March 18–22, 2015. Neurodegen Dis. 2015;15(Suppl. 1):290.
149. Forman M, Tseng J, Palcza J, Leempoels J, Ramael S, Krishna G, et al. The novel BACE inhibitor MK-8931 dramatically lowers CSF Aβ peptides in healthy subjects: results from a rising single dose study (PL02.004). Neurol. 2012;78:PL02.004.
150. Forman M, Palcza J, Tseng J, Leempoels J, Ramael S, Han D, et al. The novel BACE inhibitor MK-8931 dramatically lowers cerebrospinal fluid Aβ peptides in healthy subjects following single- and multiple-dose administration. Alzheimers Dementia. 2012;8:P704.
151. Forman M, Kleijn H-J, Dockendorf M, Palcza J, Tseng J, Canales C, et al. The novel BACE inhibitor MK-8931 dramatically lowers CSF β-amyloid in patients with mild-to-moderate Alzheimer’s disease. Alzheimers Dement. 2013;9:P139.
152. Stone J, Kleijn HJ, Dockendorf M, Ma L, Palcza J, Tseng J, et al. Consistency of BACE inhibitor-mediated brain amyloid production inhibition by MK-8931 in Alzheimer’s disease patients and healthy young adults. Alzheimers Dement. 2013;9:P690–1.
153. Min K, Forman M, Dockendorf M, Palcza J, Soni P, Ma L, et al. A study to evaluate the pharmacokinetics and pharmacodynamics of single and multiple oral doses of the novel BACE inhibitor MK-8931 in Japanese subjects. Alzheimers Dement. 2012;8:P186.
154. Haeberlein SB, Cebers G, Höglund K, Salter H, Eketjäll S, Bogstedt A, et al. AZD3293, a potent and selective orally active, brain-permeable BACE1 inhibitor. Alzheimers Dement. 2013;9:P813.
155. Eketjäll SJJ, Kaspersson K, Bogstedt A, Jeppsson F, Fälting J, Haeberlein SB, Kugler AR, Alexander RC, Cebers G. AZD3293: A novel, orally active BACE1 inhibitor with high potency and permeability and markedly slow off-rate kinetics. J Alzheimers Dis. 2016;40:1109–23.
156. Höglund K, Salter H, Zetterberg H, Andreason U, Olsson T, Alexander R, et al. Monitoring the soluble amyloid precursor protein alpha (sAPPα) and beta (sAPPβ) fragments in plasma and CSF from healthy individuals treated with BACE inhibitor AZD3293 in a multiple ascending dose study: pharmacokinetic and pharmacodynamic correlate. Alzheimers Dement. 2014;10:P447.
157. Alexander R, Budd S, Russell M, Kugler A, Cebers G, Ye N, et al. AZD3293 A novel BACE1 inhibitor: safety, tolerability, and effects on plasma and CSF Aβ peptides following single- and multiple-dose administration. Neurobiol Aging. 2014;35(Supplement 1):S2.
158. Astra Zeneca. A Two-part single and multiple dose study to assess the safety, pharmacokinetics and effects of AZD3293 in healthy Japanese young and elderly volunteers. NIH, Clinical Trialsgov 2013. https://clinicaltrials.gov/ct2/show/results?term=AZD3293&rank=9§=X5430126%29. Accessed 03 March 2016.
159. Fukushima T, Osada Y, Ishibashi A, Lucas F. Novel BACE1 inhibitor, E2609, lowers Abeta levels in the brain, cerebrospinal fluid and plasma in rats and guinea pigs. Alzheimers Dement. 2012;8:P223–4.
160. Lai R, Albala B, Kaplow JM, Aluri J, Yen M, Satlin A. First-in-human study of E2609, a novel BACE1 inhibitor, demonstrates prolonged reductions in plasma β-amyloid levels after single dosing. Alzheimers Dement. 2012;8:P96.
161. Albala B, Kaplow JM, Lai R, Matijevic M, Aluri J, Satlin A. CSF amyloid lowering in human volunteers after 14 days oral administration of the novel BACE1 inhibitor E2609. Alzheimers Dement. 2013;8:S743.
162. Bernier F, Sato Y, Matijevic M, Desmond H, McGrath S, Burns L, et al. Clinical study of E2609, a novel BACE1 inhibitor, demonstrates target engagement and inhibition of BACE1 activity in CSF. Alzheimers Dement. 2013;9:P886.
163. Timmers M, Van Broeck B, Slemmon J, et al. Profiling the dynamics of CSF and plasma Aβ reduction with JNJ-54861911, an oral BACE inhibitor. In: 12th international conference on Alzheimer’s and Parkinson’s diseases and related neurological disorders (AD/PD) Nice (France) Mar 2015.
164. Dominguez D, Tournoy J, Hartmann D, Huth T, Cryns K, Deforce S, Serneels L, Camacho IE, Marjaux E, Craessaerts K, Roebroek AJ, Schwake M, D’Hooge R, Bach P, Kalinke U, Moechars D, Alzheimer C, Reiss K, Saftig P, De Strooper B. Phenotypic and biochemical analyses of BACE1- and BACE2-deficient mice. J Biol Chem. 2005;280:30797–806.
165. Willem M, Garratt AN, Novak B, Citron M, Kaufmann S, Rittger A, DeStrooper B, Saftig P, Birchmeier C, Haass C. Control of peripheral nerve myelination by the β-secretase BACE1. Science. 2006;314:664–6.
166. Hu X, Hicks CW, He W, Wong P, Macklin WB, Trapp BD, et al. Bace1 modulates myelination in the central and peripheral nervous system. Nat Neurosci. 2006;9:1520–5.
167. Hu X, Hu J, Dai L, Trapp B, Yan R. Axonal and Schwann cell BACE1 is equally required for remyelination of peripheral nerves. J Neurosci. 2015;35:3806–14.
168. Savonenko AV, Melnikova T, Laird FM, Stewart KA, Price DL, Wong PC. Alteration of BACE1-dependent NRG1/ErbB4 signaling and schizophrenia-like phenotypes in BACE1-null mice. Proc Natl Acad Sci USA. 2008;105:5585–90.
169. Cheret C, Willem M, Fricker FR, Wende H, Wulf-Goldenberg A, Tahirovic S, et al. Bace1 and Neuregulin-1 cooperate to control formation and maintenance of muscle spindles. EMBO J. 2013;32:2015–28.
170. Kim D, Carey B, Wang H, Ingano L, Binshtok A, Wertz M, et al. BACE1 regulates voltage-gated sodium channels and neuronal activity. Nat Cell Biol. 2007;9:755–64.
171. Zhou L, Barao S, Laga M, Bockstael K, Borgers M, Gijsen H, et al. The neural cell adhesion molecules L1 and CHL1 are cleaved by BACE1 protease in vivo. J Biol Chem. 2012;287(31):25927–40.
172. Kuhn P-H, Koroniak K, Hogl S, Colombo A, Zeitschel U, Willem M, et al. Secretome protein enrichment identifies physiological BACE1 protease substrates in neurons. EMBO J. 2012;31:3157–68.
173. Cai J, Qi X, Kociok N, Skosyrski S, Emilio A, Ruan Q, et al. β-Secretase (BACE1) inhibition causes retinal pathology by vascular dysregulation and accumulation of age pigment. EMBO Mol Med. 2012;4:980–91.
174. Rochin L, Hurbain I, Serneels L, Fort C, Watt B, Leblanc P, et al. BACE2 processes PMEL to form the melanosome amyloid matrix in pigment cells. Proc Natl Acad Sci USA. 2013;110:10658–63.
175. Willem M, Tahirovic S, Busche MA, Ovsepian SV, Chafai M, Kootar S, et al. eta-Secretase processing of APP inhibits neuronal activity in the hippocampus. Nature. 2015;526:443–7.
176. Baranger K, Marchalant Y, Bonnet AE, Crouzin N, Carrete A, Paumier JM, et al. MT5-MMP is a new pro-amyloidogenic proteinase that promotes amyloid pathology and cognitive decline in a transgenic mouse model of Alzheimer’s disease. Cell Mol Life Sci. 2016;73:217–36.
177. Blennow K. The past and the future of Alzheimer’s disease CSF biomarkers—a journey towards validated biochemical tests covering the whole spectra of molecular events. Front Neurosci. 2015;9:345.
178. Snyder PJ, Kahle-Wrobleski K, Brannan S, Miller DS, Schindler RJ, DeSanti S, et al. Assessing cognition and function in Alzheimer’s disease clinical trials: do we have the right tools? Alzheimers Dement. 2014;10:853–60.
179. Lim YY, Maruff P, Pietrzak RH, Ellis KA, Darby D, Ames D, et al. Aβ; and cognitive change: examining the preclinical and prodromal stages of Alzheimer’s disease. Alzheimers Dement. 2014;10:743–51.
180. Cash DM, Rohrer JD, Ryan NS, Ourselin S, Fox NC. Imaging endpoints for clinical trials in Alzheimer’s disease. Alzheimers Res Ther. 2014;6:87.
181. Cheng X, He P, Lee T, Yao H, Li R, Shen Y. High activities of BACE1 in brains with mild cognitive impairment. Am J Pathol. 2014;184:141–7.
182. Kim DY, Gersbacher MT, Inquimbert P, Kovacs DM. Reduced sodium channel Nav1.1 levels in BACE1-null mice. J Biol Chem. 2011;286:8106–16.
183. Lauritzen I, Pardossi-Piquard R, Bauer C, Brigham E, Abraham J-D, Ranaldi S, et al. The β-secretase-derived C-terminal fragment of βAPP, C99, but not Aβ, is a key contributor to early intraneuronal lesions in triple-transgenic mouse hippocampus. J Neurosci. 2012;32:16243–55.
184. Kandalepas PC, Sadleir KR, Eimer WA, Zhao J, Nicholson DA, Vassar R. The Alzheimer’s β-secretase BACE1 localizes to normal presynaptic terminals and to dystrophic presynaptic terminals surrounding amyloid plaques. Acta Neuropathol. 2013;126:329–52.
185. Castillo-Carranza DL, Gerson JE, Sengupta U, Guerrero-Munoz MJ, Lasagna-Reeves CA, Kayed R. Specific targeting of tau oligomers in Htau mice prevents cognitive impairment and tau toxicity following injection with brain-derived tau oligomeric seeds. J Alzheimers Dis. 2014;40(Suppl 1):S97–111.
186. Sigurdsson EM. Tau immunotherapy and imaging. Neurodegener Dis. 2014;13:103–6.
187. Georgievska B, Sandin J, Doherty J, Mörtberg A, Neelissen J, Andersson A, et al. AZD1080, a novel GSK3 inhibitor, rescues synaptic plasticity deficits in rodent brain and exhibits peripheral target engagement in humans. J Neurochem. 2013;125:446–56.
188. Miguel M, Jesus A. Glycogen synthase kinase-3 (GSK-3) inhibitors for the treatment of Alzheimers disease. Curr Pharm Des. 2010;16:2790–8.
189. Llorens-Martin M, Jurado J, Hernandez F, Avila J. GSK-3β, a pivotal kinase in Alzheimer disease. Front Mol Neurosci. 2014;7:46.
190. Ly PTT, Wu Y, Zou H, Wang R, Zhou W, Kinoshita A, et al. Inhibition of GSK3β-mediated BACE1 expression reduces Alzheimer-associated phenotypes. J Clin Invest. 2013;123(1):224–35.
191. Di Martino RMC, De Simone A, Andrisano V, Bisignano P, Bisi A, Gobbi S, et al. Versatility of the curcumin scaffold: discovery of potent and balanced dual BACE-1 and GSK-3β inhibitors. J Med Chem. 2016;59:531–44.
192. Prati F, De Simone A, Armirotti A, Summa M, Pizzirani D, Scarpelli R, et al. 3,4-Dihydro-1,3,5-triazin-2(1H)-ones as the first dual BACE-1/GSK-3β fragment hits against Alzheimer’s disease. ACS Chem Neurosci. 2015;6:1665–82.